Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of KN035 in advanced multiple primary tumors
ChiCTR1800017857Phase 2Not yet recruiting
- Sponsor
- Renji Hospital
- Start
- Oct 2018
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of envafolimab in Multiple Primary Malignancy (MPM) and colorectal cancer (CRC), sponsored by Renji Hospital. Primary endpoint: Best objective response rate. Planned start Oct 2018; status: not yet recruiting.
02
Drugs
envafolimab
03
Conditions
Multiple Primary Malignancy (MPM)colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR1800017857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800017857.